Natural product scaffolds as leads to drugs

Future Medicinal Chemistry

Volumn 1, Issue 8, 2009, Pages 1415-1427

  Newman, David J ^a   Cragg, Gordon M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 ACETYLIMINO 3 DEHEXAPYRANOSYLOXY 9 DEOXO 3 OXO 6 O,11 O [2 [6 (1 PYRAZOLYL) 3 PYRIDINYLMETHOXYIMINO]PROPYLENE]ERYTHROMYCIN; 9,10 DIDEHYDROEPOTHILONE D; ACICLOVIR; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ATORVASTATIN; BETA LACTAM; CEM 101; CEPHALOSPORIN; CETHROMYCIN; CHLORDIAZEPOXIDE; CHLORTETRACYCLINE; COMPACTIN; DEFOROLIMUS; DIAZEPAM; EPOTHILONE DERIVATIVE; ERYTHROMYCIN; EVEROLIMUS; GEMCITABINE; HYPOCHOLESTEROLEMIC AGENT; MACROLIDE; MEVINOLIN; MINOCYCLINE; MONOBACTAM; NATURAL PRODUCT; OXYTETRACYCLINE; PENICILLIN G; RAPAMYCIN; SAGOPILONE; TETRACYCLINE; THIENAMYCIN; TIGECYCLINE; TOMAYMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

CLINICAL TRIAL; DRUG APPROVAL; DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO CULTURE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SHORT SURVEY;

ANTI-INFECTIVE AGENTS; ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MOLECULAR STRUCTURE;

EID: 77953434492     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.113     Document Type: Short Survey

References (88)

1. Woese CR, Kandler O, Wheelis ML. Towards a natural system of organisms: proposal for the domains archaea, bacteria and eucarya. Proc. Natl Acad. Sci. USA 87, 4576-4579 (1990).
2. Evans BE, Rittle KE, Bock MG et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31, 2235-2246 (1988).
3. Sternbach LH, Kaiser S, Reeder E. Quinazoline 3-oxide structure of compounds previously described in the literature as 3.1.4-benzoxadiazepines. J. Am. Chem. Soc. 82, 475-480 (1960).
4. Sternbach LH, Fryer RI, Metlesics W et al. Quinazolines and 1,4 benzodiazepines. VI. Halo-, methyl-, and methoxy-substituted 1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin- 2-ones. J. Org. Chem. 27, 3788-3796 (1962).
5. Sternbach LH. The discovery of librium. Agents Actions 43, 82-85 (1994).
6. Marcinkowska H, Weil S. Condensation of O-phenylene diamine with benzaldehyde. Roczniki Chemii 14, 1312-1319 (1934).
7. Arima K, Kohsaka M, Tamura G, Imanaka H, Sakai H. Tomaymycin, a new antibiotic. I. Isolation and properties of tomaymycin. J. Antibiot. 25, 437-444 (1972).
8. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem. Revs. 109, 3012-3043 (2009).
9. Newman DJ. Natural products as leads to potential drugs: an old process or the new hope for drug discovery. J. Med. Chem. 51, 2589-2599 (2008).
10. Scherlach K, Hertweck C. Triggering cryptic natural product biosynthesis in microorganisms. Org. Biomol. Chem. 7, 1753-1760 (2009).
11. Hertweck C. The biosynthetic logic of polyketide diversity. Angew. Chem. Int. Ed. 48, 4688-4716 (2009).
12. Abraham EP, Newton GGF. The structure of cephalosporin C. Biochem. J. 79, 377-393 (1961).
13. Hashimoto M, Komori T, Kamiya T. Nocardicin A and B, monocyclic b-lactam antibiotics from a Nocardia species. J. Am. Chem. Soc. 98, 3023-3025 (1976).
14. Rosenblum SB, Huynh T, Afonso A et al. Discovery of 1-(4-fluorophenyl)- (3R)-[3-(4- fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4- hydroxyphenyl)-2- azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem. 41, 973-980 (1998).
15. Holton RA, Liu JH. A novel asymmetric synthesis of cis-3-hydroxy-4- arylazetidin-2- ones. Bioorg. Med. Chem. Lett. 3 2475-2478 (1993).
16. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65, 232-260 (2001).
17. Aminov RI, Chee-Sanford JC, Garrigues N et al. Development, validation, and application of PCR primers for detection of tetracycline efflux genes of Gram-negative bacteria. Appl. Environ. Microbiol. 68, 1786-1793 (2002).
18. Barden TC, Buckwalter BL, Testa RJ, Petersen PJ, Lee VJ. 'Glycylcyclines.' 3,9-aminodoxycyclinecarboxamides. J. Med. Chem. 37, 3205-3211 (1994).
19. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J. Antimicrob. Chemother. 62, 895-904 (2008).
20. Swoboda S, Ober M, Hainer C et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J. Antimicrob. Chemother. 61, 729-733 (2008).
21. Tatsuta K, Yoshimoto T, Gunji H, Okado Y, Takahashi M. The first total synthesis of natural (-)-tetracycline. Chem. Lett. 646-647 (2000).
22. Tatsuta K, Hosokawa S. Total synthesis of selected bioactive natural products: illustration of strategy and design. Chem. Revs. 105, 4707-4729 (2005).
23. Charest MG, Siegel DR, Myers AG. Synthesis of (-)-tetracycline. J. Am. Chem. Soc. 127, 8292-8293 (2005).
24. Sun C, Wang Q, Brubaker JD et al. A robust platform for the synthesis of new tetracycline antibiotics. J. Am. Chem. Soc. 130, 17913-17927 (2008).
25. Poehlsgaard J, Douthwaite S. The bacterial ribosome as a target for antibiotics. Nat. Rev. Microbiol. 3, 870-881 (2005).
26. Schlünzen F, Harms J, Franceschi F et al. Structural basis for the antibiotic activity of ketolides and azalides. Structure 11, 329-338 (2003).
27. Wang G, Niu D, Qiu YL et al. Synthesis of novel 6,11-O-bridged bicyclic ketolides via a palladium-catalyzed bis-allylation. Org. Lett. 6, 4455-4458 (2004).
28. Xiong L, Korkhin Y, Mankin AS. Binding site of the bridged macrolides in the Escherichia coli ribosome. Antimicrob. Agents Chemother. 49, 281-288 (2005).
29. Bermudez LE, Motamedi N, Chee C et al. EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. Antimicrob. Agents Chemother. 51, 1666-1670 (2007).
30. Lewis CA, Merkel J, Miller SJ. Catalytic site-selective synthesis and evaluation of a series of erythromycin analogs. Bioorg. Med. Chem. Lett. 18, 6007-6011 (2008).
31. Duggar BM. Aureomycin; a product of the continuing search for new antibiotics. Ann. NY Acad. Sci. 51, 177-181 (1948).
32. Pickens LB, Tang Y. Decoding and engineering tetracycline biosynthesis. Metab. Eng. 11, 69-75 (2009).
33. Bergmann W, Feeney RJ. The isolation of a new thymine pentoside from sponges. J. Am. Chem. Soc. 72, 2809-2810 (1950).
34. Bergmann W, Feeney RJ. Contributions to the study of marine products. XXXII. The nucleosides of sponges I. J. Org. Chem. 16, 981-987 (1951).
35. Bergmann W, Burke DC. Contributions to the study of marine products. XL. The nucleosides of sponges. IV. Spongosine. J. Org. Chem. 21, 226-228 (1956).
36. Suckling CJ. Chemical approaches to the discovery of new drugs. Sci. Prog. 75, 323-359 (1991).
37. Lee WW, Benitez A, Goodman L, Baker BR. Potential anticancer agents. XL. Synthesis of the earlier-anomer of 9-(d-arabinofuranosyl) adenine. J. Am. Chem. Soc. 82, 2648-2649 (1960).
38. Cimino G, de Rosa S, de Stefano S. Antiviral agents from a gorgonian, Eunicella cavolini. Experientia 40, 339-340 (1984).
39. Endo A. A gift from nature: the birth of the statins. Nat. Med. 14, 1050-1052 (2008).
40. Endo A. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase. J. Med. Chem. 28, 401-405 (1975).
41. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 72, 323-326 (1976).
42. Endo A, Kuroda M, Tsujita Y. ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J. Antibiot. 29, 1346-1348 (1976).
43. Brown AG, Smale TC, King TJ, Hasenkamp R, Thompson RH. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J. Chem. Soc. Perkin Trans. 1, 1165-1170 (1976).
44. Steinberg D. An interpretive history of the cholesterol controversy. V. The discovery of the statins and the end of the controversy. J. Lipid Res. 47, 1339-1351 (2006).
45. Endo A. Monacolin K. A new hypocholesterolemic agent. J. Antibiot. 32, 852-854 (1979).
46. Endo A. Monacolin K. A new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Antibiot. 33, 334-336 (1980).
47. Vagelos RP. Are prescription drug prices too high? Science 252, 1080-1084 (1991).
48. Stokker GE, Hoffman WF, Alberts AA et al. 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors. 1. Structural modification of 5-substituted 3,5-dihydroxypentanoic acids and their lactone derivatives. J. Med. Chem. 28, 347-358 (1985).
49. Hoffman WF, Alberts AA, Cragoe Jr EJ et al. 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors. 2. Structural modification of 7-(substituted aryl)-3,5- dihydroxy-6-heptenoic acids and their lactone derivatives. J. Med. Chem. 29, 159-169 (1986).
50. Stokker GE, Alberts AA, Anderson PS et al. 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors. 3. 7-(3,5-disubstituted [1,1́-biphenyl]- 2-yl)-3,5-dihydroxy-6- heptenoic acids and their lactone derivatives. J. Med. Chem. 29, 170-181 (1986).
51. Roth BD, Ortwine DF, Hoefle ML et al. Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-pyrrol-1-ylethyl)-4-hydroxypyran-2- ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus. J. Med. Chem. 33, 21-31 (1990).
52. Sliskovic DR, Roth BD, Wilson MW, Hoefle ML, Newton RS. Inhibitors of cholesterol biosynthesis. 2. 1,3,5-trisubstituted [2-(tetrahydro-4-hydroxy- 2-oxopyran-6-yl)ethyl]pyrazoles. J. Med. Chem. 33, 31-38 (1990).
53. Rosen T, Heathcock CH. The synthesis of mevinic acids. Tetrahedron 42, 4909-4951 (1986).
54. Roth BD. The discovery and development of atorvastatin, a potent hypolipidemic agent. Prog. Med. Chem. 40, 1-22 (2002).
55. Ahmad S, Madsen CS, Stein PD et al. (3R,5S,E)-7-(4-(4-fluorophenyl)-6- isopropyl- 2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl) amino)pyrimidin-5-yl)-3,5- dihydroxyhept-6- enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3- methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential. J. Med. Chem. 51, 2722-2733 (2008).
56. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. 28, 727-732 (1975).
57. Baker H, Sidorowicz A, Sehgal SN, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J. Antibiot. 31, 539-545 (1978).
58. Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J. Antibiot. 37, 1231-1237 (1984).
59. Koehn FE. Therapeutic potential of natural product signal transduction agents. Curr. Opin. Biotech. 17, 631-637 (2006).
60. Tsang CK, Qi H, Liu LF, Zheng XFS. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 12, 112-124 (2007).
61. Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in leukaemia and other haematological malignancies. Brit. J. Haematol. 145, 569-580 (2009)
62. Foster DA, Toschi A. Targeting mTor with rapamycin: one dose does not fit all. Cell Cycle 8, 1026-1029 (2009).
63. Fernandez-Suarez M, Chen TS, Ting AY. Protein-proten interaction detection in vitro and in cells by proximity biotinylation. J. Am. Chem. Soc. 130, 9251-9253 (2008).
64. Ruan B, Pong K, Jow F et al. Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc. Natl Acad. Sci. USA 105, 33-38 (2008).
65. Abou-Gharbia M. Discovery of innovative small molecule therapeutics. J. Med. Chem. 52, 2-9 (2009).
66. Graziani EI. Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs. Nat. Prod. Rep. 26, 602-609 (2009).
67. Chambraud B, Belabes H, Fontaine-Lenoir V, Fellous A, Baulieu EE. The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation. Faseb J. 21, 2787-2797 (2007).
68. Hoefle G, Reichenbach H. Epothilone, a myxobacterial metabolite with promising antitumor activity. In: Anticancer Agents from Natural Products. Cragg GM, Kingston DGI, Newman DJ (Eds). Taylor and Francis, Oxford, UK 413-450 (2005).
69. Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubulestabilizing agents with a taxol-like mechanism of action. Cancer Res. 55, 2325-2333 (1995).
70. Giannakakou R, Gussio R, Nogales E et al. A common pharmacophore for epothilones and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl Acad. Sci. USA 97, 2904-2909 (2000).
71. He LF, Jagtap PJ, Kingston DGI, Shen HJ, Orr GA, Horwitz SB. A common pharmacophore or taxol and the epothilones based on the biological activity of a taxane molecule lacking C-13 side chain. Biochemistry 39, 3972-3978 (2000).
72. Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew. Chem. Int. Ed. 45, 7942-7948 (2006).
73. Altmann KH, Gertsch J. Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents. Nat. Prod. Rep. 24, 327-357 (2007).
74. Altmann KH, Pfeiffer B, Arseniyadis S, Pratt BA, Nicolaou KC. The chemistry and biology of epothilones-the wheel keeps turning. ChemMedChem 2, 396-423 (2007).
75. Feyen F, Cachoux F, Gertsch J, Wartmann M, Altmann K-H. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. Acc. Chem. Res. 41, 21-31 (2008).
76. Altmann KH, Memmert K. Epothilones as lead structures for new anticancer drugs - pharmacology, fermentation, and structure - activity relationships. Prog. Drug Res. 66, 275-334 (2006).
77. Hearn BR, Zhang D, Li Y, Myles DC. C-15 thiazol-4-yl analogues of (E)-9,10- didehydroepothilone D: synthesis and cytotoxicity. Org. Lett. 8, 3057-3059 (2006).
78. Cho YS, Wu KD, Moore MAS, Chou TC, Danishefsky SJ. Second-generation epothilones: discovery of fludelone and its extraordinary antitumor properties. Drugs Fut. 30, 737-745 (2005).
79. Chou TC, Zhang XG, Dong H et al. Iso-oxazole-fludelone (KOS-1803) as a potent and efficacious microtubule-stablization epothilone against xenograft tumors. Proc. Am. Assoc. Cancer Res. 1402 (2008).
80. Chou TC, Zhang X, Zhong Z et al. Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones. Proc. Natl Acad. Sci. USA 105, 13157-13162 (2008).
81. Leamon CP. Folate-targeted drug strategies for the treatment of cancer. Curr. Opin. Investig. Drugs 9, 1277-1286 (2008).
82. Frank B, Müller R. Neue wirkstoffe aus myxobakterien: wie mikroorganismen den krebs bekämpfen helfen. Pharmaz. Zeit. 152, 64-67 (2007).
83. Schneiker S, Perlova O, Kaiser O et al. Complete genome sequence of the myxobacterium Sorangium cellulosum. Nat. Biotech. 25, 1281-1289 (2007).
84. Wenzel SC, Müller R. Myxobacterial natural product assembly lines: fascinating examples of curious biochemistry. Nat. Prod. Rep. 24, 1211-1224 (2007).
85. Schimer A, Gadkari R, Reeves CD, Ibrahim F, de Long EF, Hutchinson CR. Metagenomic analysis reveals diverse polyketide synthase gene clusters in microorganisms associated with the marine sponge Discodermia dissoluta. Appl. Environ. Microbiol. 71, 4840-4849 (2005).
86. Uria A, Piel J. Cultivation-independent approach to investigate the chemistry of marine symbiotic bacteria. Phytochem. Revs. 2009, 401-414 (2009).
87. King RW, Bauer, JD, Brady SF. An environmental DNA-derived type II polyketide biosynthetic pathway encodes the biosynthesis of the pentacyclic polyketide erdacin. Angew. Chem. Int. Ed. 48, 6257-6261 (2009).
88. Piel J. Metabolites from symbiotic bacteria. Nat. Prod. Rep. 26, 338-362 (2009).